|

Targeted therapy Clinical Trials

2 actively recruiting trials

Also known as: Anlotinib (CHIATAI TIANQING PHARMACEUTICAL GROUP, China), RTK inhibitor

Pipeline

Phase 2: 2

Top Sponsors

  • Pengyuan Liu1
  • Fudan University1

Indications

  • Cancer2
  • Advanced Colorectal Carcinoma1
  • Immunotherapy1
  • Metastatic Castration-resistant Prostate Cancer (CRPC)1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.